Navigation Links
Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
Date:9/1/2010

SAN DIEGO, Sept. 1 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:

  • Robert W. Baird 2010 Health Care Conference on Tuesday, September 14, 2010 at 8:30 a.m. Eastern Time at The St. Regis Hotel in New York City.
  • UBS Global Life Sciences Conference 2010 on Tuesday, September 21, 2010 at 10:00 a.m. Eastern Time at the Grand Hyatt New York in New York City.
  • 5th Annual JMP Securities Healthcare Conference on Monday, September 27, 2010 at 9:00 a.m. Eastern Time at The New York Palace in New York City.

  • (Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

    (Logo:  http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

    Live audio webcasts of these presentations will be accessible on the Company's website at www.optimerpharma.com, under the investors section.  Replays of these presentations will be available at the same location for 30 days after the presentations.

    About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI).  In two Phase 3 trials completed by Optimer to study the safety and efficacy of fidaxomicin for the treatment of CDI, fidaxomicin was statistically superior to vancomycin in global cure rate (defined as cure with no recurre
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2

    Related medicine technology :

    1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
    2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
    3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
    4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
    5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
    6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
    7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
    8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... 2014 /PRNewswire-iReach/ -- The global microbial identification market ... applications, end users, and geographies. Genotypic technology is ... identification market. This favorable growth is attributed to ... the time required for microbial identification along with ... genotypic methods have high applications in clinical diagnostics ...
    (Date:7/29/2014)... 29, 2014 Amgen (NASDAQ: AMGN ... of 2014. Key results include: , Total revenues ... product sales growth driven by strong performance across the ... (carfilzomib), Prolia ® (denosumab) and XGEVA ® ... $2.37, driven by higher revenues and a significant increase ...
    (Date:7/29/2014)... ST. LOUIS, July 29, 2014  Express Scripts Holding ... quarter net income attributable to Express Scripts stockholders of ... per diluted share, as detailed in Table 4, was ... "We are well positioned to serve our clients with ... and to improve the health outcomes of our members," stated ...
    Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7
    (Date:7/29/2014)... Daily Gossip indicates in its Natural Vitiligo Treatment ... a popular nutritionist and health specialist. Michael Dawson suffered ... disorder, but none of them worked. , According to ... to look for an alternative vitiligo treatment, which he ... too, to become vitiligo free. , To learn ...
    (Date:7/29/2014)... 2014 Daily Gossip indicates in its Acne ... to gain beautiful and clear skin in just 30 to ... these positive results even sooner than that. The new method ... used this step by step program, too. , Mike ... years. Mike battled this condition for a decade and none ...
    (Date:7/29/2014)... (HealthDay News) -- Want young children to embrace a ... healthy is good for them. Doing so will actually ... study suggests. "Parents and caregivers who are struggling ... off simply serving the food without saying anything about ... actually is," said study authors Michal Maimaran, of Northwestern ...
    (Date:7/29/2014)... 2014 (HealthDay News) --,The time at which heart attack ... for survival, new research suggests. Showing up at ... holidays is associated with a 13 percent higher risk ... report. Every year, more than 250,000 people suffer ... of heart attack, which is caused by a complete ...
    (Date:7/29/2014)... For survivors of severe combat injuries threatening more than ... a good record of safety and effectiveness in avoiding ... Plastic and Reconstructive Surgery , the ... Plastic Surgeons (ASPS). , Experience with multiple limb ... shows good success rates, with no increase in complications ...
    Breaking Medicine News(10 mins):Health News:Natural Vitiligo Treatment System Review Reveals Michael Dawson’s New Vitiligo Cure Program 2Health News:Acne No More Review Reveals Most Effective Acne Cure Program 2Health News:Kids Will Pass on 'Healthy' Foods 2Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Good outcomes with multiple limb salvage after severe combat injuries, reports Plastic and Reconstructive Surgery 2
    ... HILL, N.C., Feb. 19 With sales forces ... the constant,demand for rep time, winning a place ... response, leading pharma companies are relying on,specialized training ... process within the hospital environment, according to recent,research ...
    ... WYE ),announced today that The Honorable Stuart R. ... Maryland, has granted Wyeth,s motion for,summary judgment in the ... al -- an alleged vaccine injury case claiming that ... autistic., Previously, the Court had granted Wyeth,s motion ...
    ... PARK, Fla., Feb. 19 Transitionz Wellness,Boutique is ... or adult, who,is a cancer survivor, is going ... is trying to get well, and we are ... of the best products and services,including wigs, hats, ...
    ... A new technique developed by a University of Central ... bacterial infections patients have so they can be treated ... strains resistant to many drugs emerge, it becomes more ... would most effectively treat them. Such quick identifications become ...
    ... new study released,today found that pending congressional legislation ... technologies would likely result,in increased prices and "provide ... released today at the National Press Club by ... and senior fellow at,the American Enterprise Institute, and ...
    ... response to recent media,reports, Roche would like to reaffirm ... medication for the 2007-2008,flu season, and that physicians and ... flu strikes., Some news reports have indicated "shortages" ... in place to ensure that Tamiflu is readily,available. If ...
    Cached Medicine News:Health News:Building an Effective Sales Force to Serve the U.S. Hospital Market 2Health News:Wyeth Wins Thimerosal-Autism Case in Maryland Court 2Health News:Wyeth Wins Thimerosal-Autism Case in Maryland Court 3Health News:Transitionz Wellness Boutique Launches with Grand Opening Discounts 2Health News:UCF technique promises to aid doctor's ability to identify, treat bacterial infections 2Health News:New Report Finds Mandatory Price Disclosure for Med Tech Would Likely Increase Prices 2Health News:Press Statement: Roche Affirms That Tamiflu(R) is in Ample Supply Nationwide 2
    ... Spaced, Expandable, Multichannel Pipettor The ... boosts productivity with an industry breakthroughequal tip ... of a slide rod. This innovation allows ... between vessels with different configurations. Adjustable ...
    ... Expandable, Multichannel Pipettor The Equalizer ... productivity with an industry breakthroughequal tip spacings ... a slide rod. This innovation allows the ... vessels with different configurations. Adjustable and ...
    ... for Unparalleled Comfort Pick one of our ... Notice the trigger and ejector positionsright where they ... pipettors are ergonomically designed to help avoid repetitive ... Productivity In The Palm Of Your Hand ...
    ... Ergonomic Design for Unparalleled Comfort Pick one ... the balance. Notice the trigger and ejector positionsright ... because our pipettors are ergonomically designed to help ... of pipetting. Productivity In The Palm Of ...
    Medicine Products: